These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 16115174)

  • 1. The cost-effectiveness of bimatoprost 0.03% in the treatment of glaucoma in adult patients--a European perspective.
    Tuil E; Hommer AB; Poulsen PB; Christensen TL; Buchholz P; Walt J; Holmstrom S
    Int J Clin Pract; 2005 Sep; 59(9):1011-6. PubMed ID: 16115174
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The cost-effectiveness of bimatoprost, latanoprost and timolol in treatment of primary open angle glaucoma in five European countries.
    Holmstrom S; Buchholz P; Walt J; Wickstrøm J; Aagren M
    Curr Med Res Opin; 2006 May; 22(5):897-905. PubMed ID: 16709311
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of monotherapy treatment of glaucoma and ocular hypertension with the lipid class of medications.
    Noecker RJ; Walt JG
    Am J Ophthalmol; 2006 Jan; 141(1 Suppl):S15-21. PubMed ID: 16389056
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A cost-effectiveness comparison of bimatoprost versus latanoprost in patients with glaucoma or ocular hypertension.
    Walt JG; Lee JT
    Surv Ophthalmol; 2004 Mar; 49 Suppl 1():S36-44. PubMed ID: 15016560
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of the effects of bimatoprost and a fixed combination of latanoprost and timolol on circadian intraocular pressure.
    Rossetti L; Karabatsas CH; Topouzis F; Vetrugno M; Centofanti M; Boehm A; Viswanathan A; Vorwerk C; Goldblum D
    Ophthalmology; 2007 Dec; 114(12):2244-51. PubMed ID: 17459480
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Markov modelled pharmacoeconomic analysis of bimatoprost 0.03% in the treatment of glaucoma as an alternative to filtration surgery in Italy.
    Christensen TL; Poulsen PB; Holmstrom S; Walt JG; Vetrugno M
    Curr Med Res Opin; 2005 Nov; 21(11):1837-44. PubMed ID: 16307705
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-offset analysis: bimatoprost versus other prostaglandin analogues in open-angle glaucoma.
    Berenson KL; Kymes S; Hollander DA; Fiscella R; Burk C; Patel VD
    Am J Manag Care; 2011 Sep; 17(9):e365-74. PubMed ID: 21902444
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Feasibility and efficacy of a mass switch from latanoprost to bimatoprost in glaucoma patients in a prepaid Health Maintenance Organization.
    Law SK; Song BJ; Fang E; Caprioli J
    Ophthalmology; 2005 Dec; 112(12):2123-30. PubMed ID: 16225924
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The more favourable cost/effectiveness ratio of latanoprost vs bimatoprost and travoprost when using normally for treatment of glaucoma].
    Soto J
    Arch Soc Esp Oftalmol; 2005 Jan; 80(1):9-10; author reply 10. PubMed ID: 15692888
    [No Abstract]   [Full Text] [Related]  

  • 10. Cost considerations in the medical management of glaucoma in the US: estimated yearly costs and cost effectiveness of bimatoprost compared with other medications.
    Goldberg LD; Walt J
    Pharmacoeconomics; 2006; 24(3):251-64. PubMed ID: 16519547
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A comparison of long-term intraocular pressure fluctuation in patients treated with bimatoprost or latanoprost.
    Simmons ST; Bernstein P; Hollander DA
    Am J Ophthalmol; 2008 Sep; 146(3):473-7. PubMed ID: 18561893
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Estimated comparative costs of achieving a 20% reduction in intraocular pressure with bimatoprost or latanoprost in patients with glaucoma or ocular hypertension.
    Fiscella R; Walt J
    Drugs Aging; 2006; 23(1):39-47. PubMed ID: 16492068
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of the effects of latanoprost, travoprost, and bimatoprost on circadian intraocular pressure in patients with glaucoma or ocular hypertension.
    Orzalesi N; Rossetti L; Bottoli A; Fogagnolo P
    Ophthalmology; 2006 Feb; 113(2):239-46. PubMed ID: 16458092
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomised crossover study comparing bimatoprost and latanoprost in subjects with primary angle closure glaucoma.
    How AC; Kumar RS; Chen YM; Su DH; Gao H; Oen FT; Ho CL; Seah SK; Aung T
    Br J Ophthalmol; 2009 Jun; 93(6):782-6. PubMed ID: 19336424
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost considerations in the medical management of glaucoma in the US: estimated yearly costs and cost effectiveness of bimatoprost compared with other medications.
    Soto J
    Pharmacoeconomics; 2006; 24(5):519-20; author reply 520-2. PubMed ID: 16706575
    [No Abstract]   [Full Text] [Related]  

  • 16. A meta-analysis of topical prostaglandin analogues intra-ocular pressure lowering in glaucoma therapy.
    Denis P; Lafuma A; Khoshnood B; Mimaud V; Berdeaux G
    Curr Med Res Opin; 2007 Mar; 23(3):601-8. PubMed ID: 17355741
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analytic review of bimatoprost, latanoprost and travoprost in primary open angle glaucoma.
    Holmstrom S; Buchholz P; Walt J; Wickstrøm J; Aagren M
    Curr Med Res Opin; 2005 Nov; 21(11):1875-83. PubMed ID: 16307709
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of latanoprost, bimatoprost, and travoprost on circadian variation of intraocular pressure in patients with open-angle glaucoma.
    Yildirim N; Sahin A; Gultekin S
    J Glaucoma; 2008; 17(1):36-9. PubMed ID: 18303382
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comments on The cost-effectiveness of bimatoprost, latanoprost and timolol in treatment of primary open angle glaucoma in five European countries.
    Soto J
    Curr Med Res Opin; 2006 Oct; 22(10):1899-901; author reply 1901-2. PubMed ID: 17022847
    [No Abstract]   [Full Text] [Related]  

  • 20. Cost-effectiveness of monotherapy treatment of glaucoma and ocular hypertension with the lipid class of medications.
    Kymes S
    Am J Ophthalmol; 2006 Aug; 142(2):354; author reply 354-5. PubMed ID: 16876536
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.